Atossa Therapeutics Staples One Contingent Value Right to Each Common Share

• Atossa Therapeutics common stock will carry one stapled contingent value right (CVR) per share at the October 19, 2026, close of business.
• CVRs will transfer only with their corresponding shares unless the board elects to detach them for separate trading.
• Shares issued subsequently will also carry one attached CVR until detachment or expiration of the CVR Agreement.
• Holders collectively will receive 25% of net proceeds from the first qualifying priority review voucher’s sale or deemed monetization, capped at $50 million.
• CVRs cover the first qualifying voucher awarded by December 31, 2036, subject to a board extension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF74933) on October 19, 2026, and is solely responsible for the information contained therein.